Personalized delivery of tumor treating fields for glioblastoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on glioblastoma patients starting treatment with Optune, which uses tumor treating fields (TTFields) to improve survival rates. Participants will be assigned to receive either standard array mapping based on regular MRI or a more precise array mapping using advanced whole brain spectroscopy techniques. This innovative approach aims to enhance treatment outcomes by accurately identifying the extent of tumor spread within the brain. The study seeks to determine if the alternative mapping method leads to better results compared to the standard approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult population ≥ 22 years
* Histologically confirmed diagnosis of GBM or molecular GBM according to c-IMPACT NOW criteria
* Have undergone maximal safe surgical resection followed by either standard full course radiation of 6000 cGy in 6 weeks or a hypofractionated course of 4000 cGy in 3 weeks
* 3 Harboring any genotype profiles (MGMT promoter methylation or unmethylation and/or isocitrate dehydrogenase (IDH) mutant or IDH wild-type)
* Possessing adequate hematological, hepatic and renal functions
* Willingness to receive TTFields

Exclusion Criteria:

* Presence of infra-tentorial GBM
* Pregnancy
* Significant co-morbidities at baseline which would prevent maintenance TMZ treatment
* Active implanted medical device, a skull defect (such as missing bone with no replacement) or bullet fragments. Examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators,pacemakers, defibrillators and programmable shunts. , other implanted electronic devices in the brain.
* Sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes.
* Presence of significant hemorrhage in and around the tumor bed that may potentially degrade the image quality.

Where it's running

• Abramson Cancer Center
  Philadelphia, Pennsylvania, United States Recruiting
• Penn Medicine, University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Suyash Mohan, MD, PDCC — University of Pennsylvania
• Study coordinator: Demetrius Lee
• Email: Demetrius.Lee@Pennmedicine.upenn.edu
• Phone: 267-408-0977

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care

  This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.

  Recruiting Phase 1 Alpheus Medical, Inc. · Buffalo, New York · NCT07862647

• Midline glioma MRI AI model: preoperative molecular subtyping and prognosis

  This study tests an MRI-based AI model to predict key molecular subtypes and prognosis for patients with midline gliomas before surgery.

  Recruiting Xiangya Hospital of Central South University · Changsha, Hunan · NCT07608003

• PET-guided surgery for high-grade glioma

  This project will try using 18F-DOPA PET to guide surgeons to remove tumor beyond MRI-visible areas in adults with high-grade glioma to see if it delays progression and extends survival.

  Recruiting at 2 sites Universita degli Studi di Genova · Torino, Turin and 1 other locations · NCT07567196

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• How Acetadote might affect metabolism in newly diagnosed glioblastoma

  This early-phase trial tests whether Acetadote can change brain tumor metabolism in adults with a new glioblastoma diagnosis.

  Recruiting Early Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07387666

• Surgery and Laser Therapy for Bilateral Glioblastoma

  This study tests surgery and laser-induced thermal therapy to treat bilateral glioblastoma in people whose tumors cross both brain hemispheres.

  Recruiting King's College Hospital NHS Trust · London · NCT07384884

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.